This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Monash University. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: James Whisstock: Innovator in Anti-Inflammatory Therapeutics
Introduction
James Whisstock is an accomplished inventor based in Australia. He has made significant contributions to the field of biomedicine, particularly in the development of therapeutics aimed at treating inflammatory diseases. His work focuses on polypeptides, including variants of interleukin-37 (IL-37), which play a crucial role in anti-inflammatory responses.
Latest Patents
James Whisstock holds a notable patent related to IL-37 variants. This invention pertains to polypeptides, including variants of interleukin-37, and their use in therapeutics and compositions. The invention also addresses methods for treating inflammatory diseases or conditions. Specifically, it provides a monomeric anti-inflammatory polypeptide that comprises an amino acid sequence of an IL-37 monomer, with modifications to prevent the peptide from forming a homodimer.
Career Highlights
Throughout his career, James Whisstock has worked with prestigious institutions such as Monash University and the Hudson Institute of Medical Research. His research has contributed to advancements in understanding and treating inflammatory conditions, showcasing his dedication to improving health outcomes.
Collaborations
James has collaborated with notable colleagues, including Marcel Nold and Claudia Nold. These partnerships have further enriched his research and development efforts in the field of anti-inflammatory therapeutics.
Conclusion
James Whisstock is a prominent figure in the realm of biomedical innovation, particularly in the development of anti-inflammatory therapeutics. His work on IL-37 variants exemplifies his commitment to addressing significant health challenges.